 |
|
Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
Morteza Entezari, Alireza Ramezani, Mehdi Yaseri
Korean J Ophthalmol. 2012;26(2):139-142. Published online 2012 Mar 22 DOI: https://doi.org/10.3341/kjo.2012.26.2.139
|
|
Citations to this article as recorded by
 Central serous chorioretinopathy: Towards an evidence-based treatment guideline
Thomas J. van Rijssen, Elon H.C. van Dijk, Suzanne Yzer, Kyoko Ohno-Matsui, Jan E.E. Keunen, Reinier O. Schlingemann, Sobha Sivaprasad, Giuseppe Querques, Susan M. Downes, Sascha Fauser, Carel B. Hoyng, Felice Cardillo Piccolino, Jay K. Chhablani, Timothy
Progress in Retinal and Eye Research.2019; 73: 100770. CrossRef Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy
Aliagha Alishiri, Khosrow Jadidi, Seyed Aliasghar Mosavi, Hamidreza Torabi
Journal of Current Ophthalmology.2019; 31(4): 406. CrossRef Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments
Pierluigi Iacono, Lisa Toto, Eliana Costanzo, Monica Varano, Maria Cristina Parravano
Current Pharmaceutical Design.2019; 24(41): 4864. CrossRef Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis
Shangli Ji, Yemei Wei, Jiansu Chen, Shibo Tang
International Journal of Clinical Pharmacy.2017; 39(3): 514. CrossRef Success of Ranibizumab in Central Serous Chorioretinopathy Resistant to Bevacizumab
Ahmet Altun, Sevda Aydin Kurna, Osman Okan Olcaysu, Tomris Sengor, Suat Fazil Aki, Tugba Gencaga Atakan
Journal of Ocular Pharmacology and Therapeutics.2014; 30(10): 842. CrossRef Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review
Y-R Chung, E J Seo, H M Lew, K H Lee
Eye.2013; 27(12): 1339. CrossRef
|